ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$2.34 USD
-0.17 (-6.77%)
Updated Sep 20, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
ProPhase Labs, Inc. - Sell
Zacks' proprietary data indicates that ProPhase Labs, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the PRPH shares relative to the market in the next few months. In addition, ProPhase Labs, Inc. has a VGM Score of F (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that ProPhase Labs, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of PRPH, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this stock lacks momentum and would be a lackluster choice for momentum investors.